COYA 303 study reports immune-signaling changes in mice exposed to inflammation

Coya Therapeutics on September 8 highlighted a published mouse study of COYA 303, its investigational combination of low-dose interleukin-2 and a GLP-1 receptor agonist. The research adds experimental support for targeting two aspects of immune regulation together, while leaving the central clinical question unanswered: whether the approach can meaningfully help people with neurodegenerative disease.

The paper appeared in the International Journal of Molecular Sciences on September 2. The company’s announcement is the new development today; the publication and experiments should not be understood as events that occurred on September 8.

### What the experiment measured

Researchers tested semaglutide, low-dose IL-2 and their combination in mice exposed to lipopolysaccharide, or LPS, an inflammatory stimulus. LPS exposure lasted five days, and treatment began 24 hours after the first exposure. This timing allowed examination of treatment after inflammatory induction had started.

The measurements concerned immune-cell populations in the spleen and gene-expression signals in selected immune cells, the cortex and the hippocampus. Semaglutide alone reduced expansion of myeloid cells, while IL-2 increased regulatory T-cell numbers and several associated regulatory transcripts.

The combination reduced inflammatory transcripts in myeloid cells and produced broader changes in brain-tissue inflammatory signatures than the individual treatments. It also enhanced selected transcripts associated with regulatory T cells. These results support complementary biological activity in this experimental setting.

### How this extends earlier work

An earlier paper, published online April 22, 2025, examined the combination in laboratory cultures of immune cells obtained from healthy human donors. Investigators isolated monocytes, regulatory T cells and responder T cells, then compared individual agents with combined treatment.

That study reported stronger suppression of inflammatory signaling and responder-cell proliferation with the combination, alongside changes in transcripts associated with regulatory-cell function and survival. Although the cells came from humans, the experiment did not administer the combination to patients or measure disease outcomes.

Together, the studies examine related questions at different levels: direct interactions among cultured immune cells and responses within a living mouse exposed to an inflammatory challenge. Agreement between those settings strengthens the rationale for further investigation, but cannot establish clinical effectiveness.

### Why the disease claims remain preliminary

An induced inflammatory response represents only part of the biology that drug developers seek to address in chronic neurodegenerative conditions. Changes in RNA transcripts also cannot, by themselves, establish durable protein-level effects, preservation of neurons or improvements in memory and daily function.

For healthspan research, the relevant unanswered question is whether changing these immune pathways ultimately preserves function over time. The reported findings do not establish that outcome, extend lifespan or demonstrate treatment benefit in Alzheimer’s disease.

Coya said the work was conducted by Houston Methodist researchers and funded through a sponsored research agreement. The company also said it would pursue partnerships and other non-dilutive avenues to advance COYA 303. Those are development intentions, rather than evidence of clinical success.

The publication therefore provides a mechanistic reason to keep investigating the combination. Progress toward a therapeutic claim would require evidence connecting these immune changes to meaningful disease outcomes, together with assessment of safety and durability in the intended patient population.